Pricing pressure for pharma continues to increase. Pharma needs to look for new and more cost efficient ways to engage and educate clinicians. MM&M brings it all into perspective.
At Blitz, we've priced out white space initiatives down to the cost per target over six months of engagement...and the numbers are amazingly low when scale and optimization techniques are employed.
Pricing pressure is the new new normal for drugmakers
Rebecca Mayer Knutsen
May 30, 2017
We probably should have seen this coming. When QuintilesIMS issued its annual report Medicines Use and Spending in the U.S. in April 2016, it disclosed that drug spends had grown by 12% in 2015 compared to 2014. But when factoring in rebates given to payers and other price concessions, that figure shrank to around 8.5%.
So nobody was entirely sure what to expect from the 2016 numbers, especially given the recent abundance of headlines along the lines of “Backlash Against Drug Prices Hits Manufacturers and Middlemen.” Such analyses signaled that in-fighting between pharma and PBMs had reached a fever pitch, which led many pundits to predict tepid growth at best. Continue reading at MM&M-